A Phase 2 interventional study of Ivosidenib in Cholangiocarcinoma Non-resectable and Cholangiocarcinoma Metastatic, sponsored by Servier. Active, not recruiting at 7 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-09.
Sponsored by Servier · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Cholangiocarcinoma with a site in Japan — 6 open to participants now, 14 under way, 3 of them phase 3. Cholangiocarcinoma · Japan.
Among the 31 studies in Cholangiocarcinoma with a site in Japan, this one is the 26th largest by enrollment of the 28 interventional ones that give a count, is one of 5 that started in 2023, is one of 8 in phase 2, reaches primary completion later than 2 of the 13 other live ones, and was the 22nd registered.
825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.
Browse Cholangiocarcinoma studies →6 of the 31 studies in Cholangiocarcinoma with a site in Japan are open now. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in Japan, United States
Ages 18+
Aichi Medical University · Sites in Japan, Korea, Republic of
Ages 18+
Eli Lilly and Company · Sites in Japan, United States, China and 2 more countries
Ages 18+
Jazz Pharmaceuticals · Sites in Japan, United States, Argentina and 22 more countries
Ages 18+
City of Hope Medical Center · Sites in Japan, United States
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 13 · Phase 3 7 · Phase 4 1
First in 2013; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 50 across 624 interventional studies indexed under Cholangiocarcinoma.
Median enrollment 163 across the 28 interventional studies, 230 across the 3 observational. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 31 have an industry lead sponsor. The 10 most frequent:
Servier is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Servier has 1 study filed under Cholangiocarcinoma — fewer than ten, so there is no comparison to draw.
3 of the studies in Cholangiocarcinoma with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05727176Taiho Oncology, Inc.Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement | 2026-12 |
| NCT02568267Hoffmann-La RocheBasket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | 2027-06-30 |
| NCT06501625Institut de Recherches Internationales ServierIvosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation | 2027-09-13 |
Add all 3 to your calendar (.ics) → With an account.
Among the 31 studies in Cholangiocarcinoma with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will enroll participants with nonresectable or metastatic cholangiocarcinoma with an Isocitrate dehydrogenase protein, 1 (IDH1) mutation, who have previously received at least 1, but no more than 2, prior regimens for advanced disease. All participants will receive ivosidenib daily throughout multiple 28 day cycles. Study treatment will be administered until participant experiences unacceptable toxicity, disease progression, or other discontinuation criteria are met. Study visits will be conducted every week during Cycle 1 (Days 1, 8, 15, and 22), every other week during Cycles 2 and 3, and Day 1 of each cycle thereafter. After the last dose of treatment, participants will attend an end of treatment and a post-treatment follow-up visit, and participants will be followed to assess overall survival. Study visits may include a tumor assessment, physical exam, electrocardiogram (ECG), blood and urine analysis, and questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
250 mg Tablets
Drug: Ivosidenib
Subjects will take 2 tablets (500 mg total) orally once daily.
6-month Progression Free Survival (PFS) Rate
Proportion of subjects who are alive and progression-free (using RECIST v1.1) at 6 months after Day 1 (C1D1) per Independent Radiology Center (IRC)
Time frame: Through 6 months after the first dose
Progression Free Survival (PFS)
The time from Day 1 to the date of first documentation of disease progression as assessed by the Investigator and by the IRC per RECIST v1.1. or death due to any cause
Time frame: Approximately 1 year
Overall Survival (OS)
Time frame: Approximately 1 year
Objective Response (OR) Rate
Complete response or partial response
Time frame: Approximately 1 year
Duration of Response (DOR)
The time from date of first documented confirmed complete response (CR) or confirmed partial response (PR) to date of first documented disease progression or death due to any cause
Time frame: Approximately 1 year
Time to Response (TTR)
The time from Day 1 to date of first documented confirmed complete response (CR) or confirmed partial response (PR)
Time frame: Approximately 1 year
Change From Baseline in Health-Related Quality of Life Using EORTC-QLQ-C30 Questionnaire Scores.
The European Organisation for Research and Treatment of Cancer - Quality Of Life Questionnaire - Core Questionnaire (EORTC-QLQ-C30) is comprised of 5 functional scales ((Physical functioning, Role functioning, Cognitive functioning, Emotional functioning and Social functioning), 3 symptom scales (Fatigue, Pain and Nausea/Vomiting), 6 additional single items (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties) and global health status (GHS). All of the scale scores range from 0 - 100; for the functional scales and GHS the higher score represents better functioning and for the symptom scales and single items the higher score represents an increase in symptoms. .
Time frame: Baseline and 1 year
Change From Baseline in Health-Related Quality of Life Using EORTC-QLQ-BIL21 Questionnaire Scores.
The European Organisation for Research and Treatment of Cancer - Quality Of Life Questionnaire - Cholangiocarcinoma and Gallbladder Cancer Module (EORTC-QLQ-BIL21) scores range from 0 - 100 with higher scores representing more severe symptoms.
Time frame: Baseline and 1 year
Average EQ-5D-5L VAS Scores
The 5-level EuroQol five dimensions questionnaire (EQ-5D-5L) visual analogue scale (VAS) scores range from 0 to 100 with a higher number representing a better health status.
Time frame: Baseline, Cycle 3 Day 1 (cycle = 28 days), and End of Treatment Visit (within 5 to 33 days after last dose of treatment, approximately 1 year total)
Total Number of Adverse Events (AEs)
Time frame: Approximately 1 year
Total Number of Participants With Adverse Events (AEs) Leading to Dose Modifications
Time frame: Approximately 1 year
Total Number of Participants With Adverse Events (AEs) Leading to Discontinuation
Time frame: Approximately 1 year
Total Number of Participants With Serious Adverse Events (SAEs)
Time frame: Approximately 1 year
Total Number of Participants With Adverse Events (AEs) Leading to Death
Time frame: Approximately 1 year
Average Area Under the Concentration-vs Time Curve From 0 to Time of Last Measurable Concentration (AUC0-t)
Time frame: Cycle 1 Day 1 and Cycle 2 Day 1
Average AUC Over 1 Dosing Interval at Steady State (AUCtau,ss)
Time frame: Cycle 2 Day 1
Average Time to Maximum Concentration (Tmax)
Time frame: Cycle 1 Day 1 and Cycle 2 Day 1
Average Maximum Concentration (Cmax)
Time frame: Cycle 1 Day 1 and Cycle 2 Day 1
Average Trough Concentration (Ctrough)
Time frame: Cycle 2 Day 1
Average Plasma 2-hydroxyglutarate (2-HG) Concentrations
Time frame: Cycle 1 Day 1 and Cycle 2 Day 1
Number of Participants With no Change, Plus 1 or Plus 2 Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status (ECOG PS) Score
From baseline to worst value of post-baseline assessments. ECOG PS scores range from 0 to 5 with 0 representing a person being fully active and 5 being the patient is dead.
Time frame: Approximately 1 year
| Milestone | Open-Label Ivosidenib |
|---|---|
| Started | 12 |
| Completed | 0 |
| Not completed | 12 |
| Withdrew: Participants still on-study | 8 |
| Withdrew: Death | 4 |
Proportion of subjects who are alive and progression-free (using RECIST v1.1) at 6 months after Day 1 (C1D1) per Independent Radiology Center (IRC)
| percentage of participants | Open-Label Ivosidenib |
|---|---|
| 6-month Progression Free Survival (PFS) Rate | 25.0 (8.1 to 46.5) |
The time from Day 1 to the date of first documentation of disease progression as assessed by the Investigator and by the IRC per RECIST v1.1. or death due to any cause
| months | Open-Label Ivosidenib |
|---|---|
| Progression Free Survival (PFS) | 4.21 (2.69 to NA) |
| months | Open-Label Ivosidenib |
|---|---|
| Overall Survival (OS) | NA (5.19 to NA) |
Complete response or partial response
| Participants | Open-Label Ivosidenib |
|---|---|
| Objective Response (OR) Rate | 0 |
The time from date of first documented confirmed complete response (CR) or confirmed partial response (PR) to date of first documented disease progression or death due to any cause
No measurements were reported for this outcome.
The time from Day 1 to date of first documented confirmed complete response (CR) or confirmed partial response (PR)
No measurements were reported for this outcome.
The European Organisation for Research and Treatment of Cancer - Quality Of Life Questionnaire - Core Questionnaire (EORTC-QLQ-C30) is comprised of 5 functional scales ((Physical functioning, Role functioning, Cognitive functioning, Emotional functioning and Social functioning), 3 symptom scales (Fatigue, Pain and Nausea/Vomiting), 6 additional single items (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties) and global health status (GHS). All of the scale scores range from 0 - 100; for the functional scales and GHS the higher score represents better functioning and for the symptom scales and single items the higher score represents an increase in symptoms. .
| score on a scale | Open-Label Ivosidenib |
|---|---|
| Physical Functioning | -6.7 ± 15.63 |
| Role Functioning | -9.3 ± 16.90 |
| Cognitive Functioning | -1.9 ± 10.02 |
| Emotional Functioning | -8.3 ± 18.63 |
| Social Functioning | -14.8 ± 17.57 |
| Fatigue | 7.4 ± 16.67 |
| Pain | 7.4 ± 32.39 |
| Nausea/Vomiting | 7.4 ± 12.11 |
| Dyspnea | 22.2 ± 40.82 |
| Insomnia | 18.5 ± 29.40 |
| Appetite Loss | 7.4 ± 32.39 |
| Constipation | -7.4 ± 14.70 |
| Diarrhea | 3.7 ± 20.03 |
| Financial Difficulties | 0.0 ± 23.57 |
| GHS | -20.4 ± 22.48 |
The European Organisation for Research and Treatment of Cancer - Quality Of Life Questionnaire - Cholangiocarcinoma and Gallbladder Cancer Module (EORTC-QLQ-BIL21) scores range from 0 - 100 with higher scores representing more severe symptoms.
| score on a scale | Open-Label Ivosidenib |
|---|---|
| Change From Baseline in Health-Related Quality of Life Using EORTC-QLQ-BIL21 Questionnaire Scores. | 8.3 ± 12.50 |
The 5-level EuroQol five dimensions questionnaire (EQ-5D-5L) visual analogue scale (VAS) scores range from 0 to 100 with a higher number representing a better health status.
| score on a scale | Open-Label Ivosidenib |
|---|---|
| Baseline | 78.8 ± 10.80 |
| Cycle 3 Day 1 | 75.8 ± 15.61 |
| End of Treatment | 61.7 ± 27.05 |
| Number of Adverse Events | Open-Label Ivosidenib |
|---|---|
| Total Number of Adverse Events (AEs) | 24 |
| Participants | Open-Label Ivosidenib |
|---|---|
| Total Number of Participants With Adverse Events (AEs) Leading to Dose Modifications | 0 |
| Participants | Open-Label Ivosidenib |
|---|---|
| Total Number of Participants With Adverse Events (AEs) Leading to Discontinuation | 0 |
| Participants | Open-Label Ivosidenib |
|---|---|
| Total Number of Participants With Serious Adverse Events (SAEs) | 2 |
| Participants | Open-Label Ivosidenib |
|---|---|
| Total Number of Participants With Adverse Events (AEs) Leading to Death | 0 |
| ng*h/mL | Open-Label Ivosidenib |
|---|---|
| Cycle 1 Day 1 | 18699 ± 43.5 |
| Cycle 2 Day 1 | 22404 ± 27.4 |
| ng*h/mL | Open-Label Ivosidenib |
|---|---|
| Average AUC Over 1 Dosing Interval at Steady State (AUCtau,ss) | 74121 ± 30.0 |
| hours | Open-Label Ivosidenib |
|---|---|
| Cycle 1 Day 1 | 2.98 (1.85 to 5.93) |
| Cycle 2 Day 1 | 3.83 (1.83 to 3.97) |
| ng/mL | Open-Label Ivosidenib |
|---|---|
| Cycle 1 Day 1 | 4918 ± 42.7 |
| Cycle 2 Day 1 | 4781 ± 22.8 |
| ng/mL | Open-Label Ivosidenib |
|---|---|
| Average Trough Concentration (Ctrough) | 2058 ± 28.7 |
| ng/mL | Open-Label Ivosidenib |
|---|---|
| Cycle 1 Day 1 | 597 ± 532.07 |
| Cycle 2 Day 1 | 79.95 ± 41.166 |
From baseline to worst value of post-baseline assessments. ECOG PS scores range from 0 to 5 with 0 representing a person being fully active and 5 being the patient is dead.
| Participants | Open-Label Ivosidenib |
|---|---|
| Baseline Score of 0 and Worst Post-Baseline Score of 0 (no change) | 7 |
| Baseline Score of 0 and Worst Post-Baseline Score of 1 (+1 change) | 2 |
| Baseline Score of 0 and Worst Post-Baseline Score of 2 (+2 change) | 1 |
| Baseline Score of 1 and Worst Post-Baseline Score of 1 (no change) | 2 |
Collected over Approximately 1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open-Label Ivosidenib | 4/12 (33.3%) | 2/12 (16.7%) | 9/12 (75%) |
| Event | Open-Label Ivosidenib |
|---|---|
| Electrocardiogram QT prolongedInvestigations | 2/12 |
| Event | Open-Label Ivosidenib |
|---|---|
| DiarrheaGastrointestinal disorders | 2/12 |
| HypokalaemiaMetabolism and nutrition disorders | 2/12 |
| Dry mouthGastrointestinal disorders | 1/12 |
| DyspepsiaGastrointestinal disorders | 1/12 |
| NauseaGastrointestinal disorders | 1/12 |
| StomatitisGastrointestinal disorders | 1/12 |
| VomitingGastrointestinal disorders | 1/12 |
| FatigueGeneral disorders | 1/12 |
| MalaiseGeneral disorders | 1/12 |
| PyrexiaGeneral disorders | 1/12 |
| Age, Continuous(years) | Open-Label Ivosidenib |
|---|---|
| Median | 61.5 ± 12.27 |
| Age, Customized(Participants) | Open-Label Ivosidenib |
|---|---|
| 45-<65 years old | 7 |
| >=65 years old | 5 |
| Sex: Female, Male(Participants) | Open-Label Ivosidenib |
|---|---|
| Female | 5 |
| Male | 7 |
| Race/Ethnicity, Customized(Participants) | Open-Label Ivosidenib |
|---|---|
| Not Hispanic or Latino | 12 |
| Race/Ethnicity, Customized(Participants) | Open-Label Ivosidenib |
|---|---|
| Asian | 12 |
| Body Mass Index (BMI)(kg/m^2) | Open-Label Ivosidenib |
|---|---|
| Mean | 23.1 ± 4.39 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data. Access can be requested for all interventional clinical studies: used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US). where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope. In addition, access can be requested for all interventional clinical studies in patients: sponsored by Servier with a first patient enrolled as of 1 January 2004 onwards for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: After Marketing Authorization in EEA or US if the study is used for the approval.
Access criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.
Data sharing details ↗ · clinicaltrials.servier.com
Ran from Oct 2023 to primary completion in Oct 2024, 11 months.
Results were first posted in Dec 2025, 1 year 2 months after primary completion.
Of 173 phase 2 interventional studies under Cholangiocarcinoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivosidenib
Servier